Intravascular catheters and biofilm control

Journal of Vascular Access

Volumn 8, Issue 2, 2007, Pages 69-80

  Percival, S L ^a   Kite, Peter ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Antimicrobial locks; Biofilms; Intravascular catheters

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIOCIN; BENZALKONIUM CHLORIDE; CEFAZOLIN; CHLORHEXIDINE; CIPROFLOXACIN; CITRATE SODIUM; CITRATE TRISODIUM; CITRIC ACID; EDETIC ACID; EPIDERMIN; EPIRUDIN; ERYTHROMYCIN; GENTAMICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; NAFCILLIN; NEUTROLIN; PLATINUM; POVIDONE; RIFAMPICIN; SILVER; SULFADIAZINE SILVER; TAUROLIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; BIOFILM; BLEEDING; BLOOD DISEASE; CANDIDA; CATHETER CARE; CATHETER INFECTION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; CLINICAL COMPETENCE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST BENEFIT ANALYSIS; COST CONTROL; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FATIGUE; GOOD CLINICAL PRACTICE; HAND WASHING; HEALTH CARE COST; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INDWELLING CATHETER; INFECTION PREVENTION; INFECTION RISK; INSTRUMENT STERILIZATION; INTERMETHOD COMPARISON; INTRAVASCULAR CATHETER; MATERIAL COATING; MEDICAL EDUCATION; MICROBIAL COLONIZATION; MICROBIAL CONTAMINATION; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SEPSIS; SKIN DECONTAMINATION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 34447340902     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980700800202     Document Type: Review

References (132)

1. Bacuzzi A, Cecchin A, Del Bosco A, Cantone G, Cuffari S. Recommendations and reports about central venous catheter-related infection. Surg Infect (Larchmt) 2006; 7: S65-7.
2. Richards M, Edwards J, Culver D, Gaynes R. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-92.
3. Anon. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morb Mortal Wkly Rep 2002; 51: 1-29.
4. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing haemodialysis. Ann Intern Med 1997; 127: 275-80.
5. Costerton J, Stewart P, Greenberg E. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
6. Anaissie E, Samonis G, Kontoyiannis D, et al. Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections. Eur J Clin Microbiol Infect Dis 1995; 14: 134-7.
7. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey G. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168: 400-7.
8. Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-1601.
9. Maki DG. Yes, Virginia, aseptic technique is very important: maximal barrier precautions during insertion reduce the risk of central venous catheter-related bacteremia. Infect Control Hosp Epidemiol 1994; 15: 227-30.
10. Darouiche R. Device-associated infections: a macro-problem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-72.
11. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391-402.
12. Pittet D. Nosocomial bloodstream infections. In: Wenzel RP, ed. Prevention and control of nosocomial infections. 3rd ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1997: 711-69.
13. Snydman DR. Prevention of catheter and intravascular device-related infections: a quality-of-care mandate for institutions and physicians. Mayo Clin Proc 2006; 81: 1151-2.
14. Crinch C, Maki D. The promise of novel technology for the prevention of intravascular device-related bloodstream infection, I: pathogenesis and short-term devices. Clin Infect Dis 2002; 34: 1232-42.
15. Maki DG, Stolz SM, Wheeler S, Mermel LA. 1997. Prevention of central venous catheters-realted bloodstream infection by use of an antiseptic-impregnated catheter: randomised, controlled trial. Ann Intern Med 1997; 127: 257-66.
16. Edgeworth JD, Treacher DE, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27: 1421-8.
17. Linares J, Sitges-Serra A, Garau J, Perez JL, Martin R. Pathogenesis of catheter sepsis: a prospective study with quantitative and semi quantitative cultures of catheter hub and segments. J Clin Microbiol 1985; 21: 357-60.
18. Mermel L, Stolz S, Maki DG. Epidemiology and pathogenesis of infection with Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med 1991; 91(3B): 197S-205S.
19. Conly J, Stein K, Peters B. The pathogenesis of catheter-related infection in central venous catheters using gauze versus transparent dressings. In: Wadstrom T, Eliasson I, Holder I, Ljungh A eds. Pathogenesis of wound and biomaterial associated infections. London: Springer Verlag, 1990: 508-17.
20. O'Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002; 30: 476-89.
21. Raad I, Hanna H. Intravascular catheter-related infections. Arch Intern Med 2002; 162: 871-8.
22. Marciante KD, Veenstra DL, Lipsky BA, et al. 2003. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control 2003; 31: 1.
23. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis 2003; 37: 65-72.
24. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System. Am J Cardiol 1998; 82: 789-93.
25. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993; 16: 778-84.
26. Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infection in critically ill patients. Am J Resp Crit Care Med 2000; 162: 1027.
27. Sherertz RJ. Pathogenesis of vascular catheter infections. In: F. A. Waldvogel and A. L. Bisno, eds. Infections associated with indwelling medical devices, 3rd ed. Washington: ASM Press, D.C. 2000; 111-25.
28. Characklis WG, McFeters GA, Marshall KC. 1990 Physiological ecology in biofilm systems, p341-394. In: WG Characklis ad Marshall KC (ed.) Biofilms. John Wiley and Sons Inc, New York.
29. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit Care Med 1996; 24: 1482-9.
30. Herrmann M, et al. Fibronectin, fibrinogen and laminin act as mediators of adherence of clinical staphylococcocal isolates to foreign material. J Infect Dis 1988; 158: 693-701.
31. Nilsson M, Frykberg L, Flock JL, Pei L, Lindberg M, Guss B. A fibrinogen-binding protein of Staphylococus epidermidis. Infect Immun 1998; 66: 2666-73.
32. DeMuri GP, Hostetter MK. Evidence for B1 integrin fibronectin receptor in Candida tropicalis. J Infect Dis 1996; 174: 127-32.
33. Passerini L, Lan K, Costerton J, King E. Biofilms on indwelling vascular catheters. Crit Care Med 1992; 20: 665-73.
34. Percival SL, Bowler P. Biofilms and their potential role in wound healing. Wounds 2004; 16: 234-40.
35. Moss AH, Vasilakis C, Holley JL, Foulks CJ, Pillai K, McDowell DE. Use of a silicone dual lumen catheter with a Darcon cuff as a long term vascular access for hemodialysis patients. Am J Kidney Dis 1990; 16: 211-5.
36. Donlan R. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-92.
37. Pascual A, Ramirez de Arellano E, Martinez-Martinez L, Perea EJ. Effect of polyurethane catheters and bacterial biofilms on the in vitro activity of antimicrobial agents against Staphylococcus epidermidis. J Hosp Infect 1993; 24: 211-8.
38. Ramirez de Arellano E, Pascual A, Martinez Martinez L, Perea EJ. Activity of eight antibacterial agents on Staphylococcus epidermidis attached to Teflon catheters. J Med Microbiol 1994; 40: 43-7.
39. Parras F, Ena J, Bouza E, et al. Impact of an educational program for the prevention of colonization of intravascular catheters. Infect Control Hosp Epidemiol 1994; 15: 239-42.
40. Ena J, Cercenado E, Martinez D, Bouza E. Cross-sectional epidemiology of phlebitis and catheter-related infections. Infect Control Hosp Epiderniol 1992; 13: 15-20.
41. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control 2006; 34: 476-83.
42. Moro ML, Vigano EF, Cozzi Lepri A. Risk factors for central venous catheter-related infections in surgical and intensive care units. The Central Venous Catheter-Related Infections Study Group. Infect Control Hosp Epidemiol 1994; 15: 253-64.
43. Hoffman KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. JAMA 1992; 267: 2072-6.
44. Hannan M, Juste RN, Umasanker S, et al. Antispetic-bonded central venous catheters and bacterial colonization. Anaesthesia 1999; 54: 868-72.
45. Loo S, van Heerden PV, Golleege CV, Roberts BL, Power BM. Infection in central lines:antiseptic-impregnated vs. standard non-impregnated catheters. Anaesth Intens Care 1997; 25: 637-9.
46. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregrianted central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn Microbiol Infect Dis 2000; 38: 1-5.
47. Logghe C, Van-Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997; 37: 145-56.
48. Maki D, Ringer M, Alvarado C. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338: 339-43.
49. Soifer N, Borzak S, Edlin B, Weinstein R. Prevention of peripheral venous catheter complications with an intravenous therapy team. Arch Intern Med 1998; 158: 473-7.
50. Modak SM, Sampath L. Development and evaluation of a new polyurethane central venous antiseptic catheter: reducing central venous catheter infections. Complications in Surgery 1992; 11: 23-9.
51. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics:evaluation of the risk of bacterial resistance to the antimicrobials in the catheter. Infect Control Hosp Epidemiol 2001; 22: 640-6.
52. Greenfield JL, Sampath L, Popilskis SJ, Brunnert SR, Stylianos S, Modak S. Decreased bacterial adherence and biofilm formation on chlorhexidine and silver sulfadiazine impregnated central venous catheters implanted in swine. Crit Care Med 1995; 23: 894-900.
53. Sampath LA, Chowdhury N, Caraos L, Modak SM. Infection resistance of surface modified catheters with either short-lived or prolonged activity. J Hosp Infect 1995; 30: 201-10.
54. Veenstra D, Saint S, Saba S, Lumley T, Sullivan S. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA 1999; 281: 261-7.
55. Trooskin SZ, Donetz AP, Harvey RA, Greco RS. Prevention of catheter sepsis by antibiotic bonding. Surgery 1985; 97: 547-51.
56. Darouiche R, Raad I, Heard S, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999; 340: 1-8.
57. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998; 158: 81-7.
58. Bach A, Schmidt H, Bottiger B et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother 1996; 37: 315-22.
59. Tennenberg S, Leser M, McCurdy B, et al. A prospective randomized trial of an antibiotic and antiseptic coated central venous catheter in the prevention of catheter related infection. Arch Surg 1997; 132:1348-51.
60. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnanted cental venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol 1997; 14: 428-31.
61. Raad I, Hachem R, Zermeno A, Dumo M, Bodey G. In vitro antimicrobial efficacy of silver iontophoretic catheter. Biomaterials 1996; 17: 1055-9.
62. Yorganci K, Krepel C, Weigelt JA, Edmiston C. In vitro activity of three different types of antibiotic/antibacterial coated/integrated central venous catheters against Gram-positive bacteria. Clin Microbiol Infect 2001; 7: 219.
63. Walder B, Pittet D, Tramer MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect Control Hosp Epidemiol 2002; 23: 748-56.
64. Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003; 115: 352-7.
65. Tacconelle E, Tumbarello M, Cauda R. Central venous catheters and bloodstream infection. JAMA 2000; 283: 478-9.
66. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continous quality improvement project. Chest 1999; 115: 1632-40.
67. Veenstra D, Saint S, Sullivan S. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999; 282: 554-60.
68. Loertzer H, Soukup J, Haniza A, et al. Use of catheters with the AgION antimicrobial system in kidney transplant recipients to reduce infection risk. Transplant Proc 2006; 38: 707-10.
69. Stoiser B, Kofler J, Staudinger T, et al. Contamination of central venous catheters in immunocompromised patients: a comparison between two different types of central vevous catheters. J Hosp Infect 2002; 50: 202-6.
70. Bong JJ, Kite P, Wilcox MH, McMahon MJ. Prevention of catheter related bloodstream infection by silver iotophoretic central venous catheters: a randomised control trial. J Clin Pathol 2003; 56: 731-5.
71. Osma S, Kahveci SF, Kaya FN, et al. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit. J Hosp Infect 2006; 62: 156-62.
72. Moss HA, Tebbs SE, Faroqui MH, et al. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur J Anaesthesiol 2000; 17: 680-7.
73. Oda T, Hamasaki J, Kanda N, Mikami K. Anaphylactic shock induced by an antiseptic-coated central nervous (sic venous) catheter. Anesthesiology 1997; 87: 1242-4.
74. Anon. Centers for Devices and Radiological Health, US Food and Drug Administration. FDA public health notice: potential hypersensitivity reactions to chlorhexidine-impregnated medical devices. 1998. Available at: http://www.fda.gov/cdrh/chlorhex.html.
75. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173: 418-24.
76. Vercaigne LM, Zelenitsky SA, Findlay I, Bernstein K, Penner SB. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49: 693-6.
77. Manierski C, Besarab A. Antimicrobial locks: putting the lock on catheter infections. Adv Chronic Kidney Dis 2006; 13: 245-58.
78. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 2006; 48: 596-605.
79. Fortun J, Grill F, Martin-Davila P, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58: 816-21.
80. Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57: 1110-5.
81. Segarra-Newnham M, Martin-Cooper EM. Antibiotic lock technique: a review of the literature. Ann Pharmacother 2005; 39: 311-8.
82. Carratalà J, Niubó J, Fernández-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999; 43: 2200-4
83. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and the thrombotic events in immmunocompromised children by the use of vancomycin/ciprofloxacin/ heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 2000; 18: 1269-78.
84. Rubie H, Juricic M, Claeyssens S, et al. Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer. Arch Dis Child 1995; 72: 325-9.
85. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 1990; 8: 1591-7.
86. Sherertz RJ, Boger MS, Collins CA, Mason L, Raad I. Comparative in vitro efficacies of various catheter lock solutions Antimicrob Agents Chemother 2006; 50: 1865-8.
87. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 78-83.
88. Jurewitsch B. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. J Parenter Enteral Nutr 1998; 22: 242-4.
89. Shah CB, Mittelman MW, Costerton JW, et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46: 1674-9.
90. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumour necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991; 3: 568-75.
91. Browne M K, Leslie GB, Pfirrmann RW. Taurolin, a new chemotherapeutic agent. J Appl Bacteriol 1976; 41: 363-8.
92. Gorman SP, McCafferty DF, Wolfson AD, Jones DS. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent. J Appl Bacteriol 1987; 62: 315-20.
93. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-4.
94. Alderson L, Sampath P, Darnowski JW, Calabresi P. Phase I/II clinical and pharmacologic studies with taurolidine in patients with recurrent glioblastoma multiforme. Abstracts of the 2001 American Society of Clinical Oncology Annual Meeting, abstr. 2061. 18 Dec 2005.
95. Rutala WA, Barbee SL, Aguiar NC, Sobsey MD, Weber DJ. Antimicrobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol 2000; 21: 33-8.
96. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheters. J Pediatr Hematol Oncol 2003; 25: 616-21.
97. Anonymous. 10 June 2005, accession date. Ethanol. Micromedex Healthcare Series, vol. 124. Thomson Micromedex, Greenwood Village, Colorado.
98. Fleming M, Mihic SJ, Harris RA. Ethanol, In: Hardman JG, Limbird LE, eds. Goodman and Gillman's the pharmacological basis of therapeutics, 3rd ed. New York: N.Y. McGraw-Hill, 2001; p. 429-45.
99. Sissons CH, Wong L, Cutress TW. Inhibition by ethanol of the growth of biofilm and dispersed microcosm dental plaques. Arch Oral Biol 1996; 41: 27-34.
100. Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med 2006; 160: 1049-53.
101. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. J Parenter Enteral Nutr 1987; 11: 507-8.
102. Raad I. Intravascular-catheter-related infections. Lancet 1998; 351: 893-8.
103. Raad I, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-6.
104. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998; 114: 207-13
105. Werlin SL, Lausten T, jessen S, et al. Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. J Parenter Enteral Nutr 1995; 19: 416-8.
106. Raad I, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-208.
107. Reinmuller J. The influence of taurolidine on physiological and pathological blood coagulation and implications for its use. Zentralbl Chir 1999; 124: 13-18.
108. Metcalf SCL, Chambers ST, Pithie AD, Use of ethanol locks to prevent recurrent central line sepsis. J Infect Volume 2004; 49: 20-2.
109. Mandolfo S, Borlandelli S, Elli A. Catheter lock solutions: it's time for a change. J Vase Access 2006; 7: 99-102.
110. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters -an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007; 22: 471-6.
111. Ash SR et al. Concentrated sodium citrate (23 %) for catheter lock. Hemodialysis Int 2000; 4: 22-31.
112. Sodemann K, Polaschegg HD, Feldmer B. Two years' experience with Dialock® and CLS™ (a new antimicrobial lock solution). Blood Purif 2001; 19: 251-4.
113. Sodemann K. Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof US Patent No 6, 166, 007, Issued Dec 26, 2000.
114. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-2000.
115. Mittleman MW, Pelak M, Shah C, Costerton JW. Eradication of microbial biofilms with an antimicrobial catheter-lock solution (abstract) General Meeting of American Society of Microbiology, May 2001.
116. Mermel LA, Parenteau S. Efficacy of the Biolink Catheter Lock Solution (CLS™) for Dialock® hemodialysis access port and catheters - An in vitro model (abstract). 4th Devennial International Conference on Nosocomial and Healthcare-Associated Infections, March 2000.
117. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21: 2247-55.
118. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM. Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007; 22: 477-83.
119. Kite P, Eastwood K, Sugden S, Percival SL. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol 2004; 42: 3073-6.
120. Kite P, Eastwood K, Percival SL. Catheters and control of infection. In: McBain A, Allison D, Pratten J, Spratt D, Upton M, Vcrran J, eds. Biofilms, Persistence and Ubiquity, 2005. September 6-8th, Bioline, Cardiff.
121. Riley MA, Wertz JE. Bacteriocins: Evolution, ecology, and application. Annu Rev Microbiol 2002; 56: 117-37.
122. Fontana MBC, Basto Freire de MDC, Brandelli A. Bacteriocins Pep5 and Epidermin inhibit Staphylococus epidermidis adhesion to catheters. Current Microbiology 2006; 52: 350-3.
123. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50: 1268-75.
124. Russell AD, Day MJ. Antibiotics and biocide resistance in bacteria. Microbios 1996; 85: 45-65.
125. Russell AD, Unchalee T, Maillard JY, Furr JR. Possible link between bacterial resistance and the use of antibiotics and biocides. Antimicrob Agents Chemother 1998; 42: 2151.
126. Percival SL, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect Control Hosp Epidemiol 2005; 26: 515-9.
127. Raad I, Buzaid A, Rhyne J, et al. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997; 25: 149-51.
128. Bassetti S, D'Agostino R, Sherertz R. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother 2001; 45: 1535-8.
129. Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother 2001: 47: 589-98.
130. Munson EL, Heard SO, Doern GV. In vitro exposure of bacteria to antimicrobial impregnated central venous catheters does not directly lead to the emergence of antimicrobial resistance. Chest 2004; 126: 1628-35.
131. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004; 126: 1612-8.
132. Steele L, Solomon S, Kritchevsky S, et al. Correlation between HICPAC recommendations for the prevention of intravascular device-related infections and reported practices in 53 hospitals participating in the evaluation of processes and indicators in infections control study [abstract]. Am J Infect Control 2000; 28: 89.